NCT00507130 - A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions

Asthma

Interventions

BIOLOGICAL

MEDI528 0.3 mg/kg

MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks

BIOLOGICAL

MEDI528 1 mg/kg

MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks

BIOLOGICAL

MEDI528 3 mg/kg

MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks

OTHER

PLACEBO

Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks

Trial Locations (9)

North Carolina Clinical Research, Raleigh

Spartanburg Medical Research, Spartanburg

Toledo Center for Clinical Research, Sylvania

Clinical Research Institute, Inc., Minneapolis

Colorado Allergy & Asthma Centers, PC, Denver

Northeast Medical Research Associates, Inc., North Dartmouth

McMaster University, Hamilton

Hôpital du Sacré-Coeur de Montréal, Montreal

Hopital Laval, Québec